How long does it take for Dasatinib/Startase to take effect?

Dasatinib (Dasatinib), as a targeted therapy, has demonstrated significant efficacy in the treatment of Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) and acute lymphoblastic leukemia (Ph+ ALL). However, the time it takes for the drug to take effect varies depending on the patient's condition, response to treatment, and individual differences.

In most patients, dasatinib usually begins to take effect quickly. For patients with chronic phasePh+ CML, a significant reduction in leukemia cells and an improvement in the white blood cell count in the blood are usually observed within a few weeks of treatment. In some patients, a clear clinical response is seen within weeks of treatment, with white blood cell counts gradually returning to the normal range. For these patients, the therapeutic effect of dasatinib is relatively rapid, especially in the initial treatment stage, when the effect is usually more obvious.

For patients with Ph+ CML in the accelerated or acute phasethe drug may take a slightly longer time to take effect. This is because the conditions of these patients are more complex, leukemia cells proliferate faster, and treatment response may take longer. Despite this, most patients still show therapeutic effects and have their disease effectively controlled within a few months of dasatinib treatment.

For Ph+ ALL patients, especially those who have become resistant or intolerant after receiving other anti-leukemia drugs, the therapeutic effect of dasatinib usually begins to appear within weeks to months. Because acute-stage leukemia progresses more quickly, the effects of the drug may appear more quickly, especially when used in combination with chemotherapy.

As a targeted drug, dasatinib can show a certain effect within a few weeks during treatment, but the time it takes to completely control the disease depends on multiple factors, including individual differences among patients, drug resistance of the disease, and treatment compliance. Patients should undergo regular blood tests and other related examinations during treatment so that doctors can evaluate the treatment effect and adjust the treatment plan.

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/sprycel